Category: 103-16-2

Lycorine improves peripheral nerve function by promoting Schwann cell autophagy via AMPK pathway activation and MMP9 downregulation in diabetic peripheral neuropathy was written by Yuan, Qingqing;Zhang, Xiang;Wei, Wandi;Zhao, Jialing;Wu, Yuhao;Zhao, Song;Zhu, Lin;Wang, Peiran;Hao, Jun. And the article was included in Pharmacological Research in 2022.Electric Literature of C13H12O2 The following contents are mentioned in the article:

Diabetic peripheral neuropathy (DPN) is the most common complication of diabetes mellitus and no effective therapy is approved. Here, lycorine, a natural alkaloid, was identified as a potential drug for DPN by the bioinformatics anal. of GEO datasets and Connectivity Map database. Lycorine administration improved peripheral nerve function and autophagy-associated proteins of diabetic mice. Again, in vitro high glucose-cultured rat Schwann cells (RSC96) showed enhanced autophagosome marker LC3-II with the treatment of lycorine. Addnl., beclin-1 and Atg3 were decreased in high glucose-stimulated RSC96 cells, which were reversed by lycorine treatment. Furthermore, DPN-associated differentially expressed genes (DEGs) from GEO datasets and lycorine-drug targets from PubChem and PharmMapper were visually analyzed and revealed that MMP9 was both DPN-associated DEGs and lycorine-drug target. Functional enrichment anal. of MMP9-relevant genes showed that cell energy metabolism was involved. Moreover, lycorine reduced high glucose-enhanced MMP9 expression in RSC96 cells. Overexpression of MMP9 attenuated lycorine-induced the expression of beclin-1, Atg3 and LC3-II in high glucose-cultured RSC96 cells. In addition, AMPK pathway activation was confirmed in lycorine-treated high glucose-cultured RSC96 cells. Then AMPK pathway inhibition attenuated lycorine-reduced MMP9 expression in high glucose-treated RSC96 cells. Mol. docking anal. revealed that lycorine bound the domain of AMPK containing Thr 172 site, which affected AMPK (Thr 172) phosphorylation. Finally, AMPK pathway activation and MMP9 downregulation were also revealed in the sciatic nerves of diabetic mice administrated with lycorine. Taken together, lycorine was advised to promote Schwann cell autophagy via AMPK pathway activation and MMP9 downregulation-induced LC3-II transformation in diabetic peripheral neuropathy. This study involved multiple reactions and reactants, such as 4-Benzyloxyphenol (cas: 103-16-2Electric Literature of C13H12O2).

4-Benzyloxyphenol (cas: 103-16-2) belongs to ethers. Carboxylic acid esters of low molecular weight are colourless, volatile liquids with pleasant odours, slightly soluble in water. Esterification is the general name for a chemical reaction in which two reactants (typically an alcohol and an acid) form an ester as the reaction product. Esters are common in organic chemistry and biological materials.Electric Literature of C13H12O2

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem

Identification of potential drugs for diffuse large b-cell lymphoma based on bioinformatics and Connectivity Map database was written by Luo, Bin;Gu, Yong-yao;Wang, Xiao-dong;Chen, Gang;Peng, Zhi-gang. And the article was included in Pathology, Research and Practice in 2018.Electric Literature of C13H12O2 The following contents are mentioned in the article:

Diffuse large B-cell lymphoma (DLBCL) is the most main subtype in non-Hodgkin lymphoma. After chemotherapy, about 30% of patients with DLBCL develop resistance and relapse. This study was to identify potential therapeutic drugs for DLBCL using the bioinformatics method. The differentially expressed genes (DEGs) between DLBCL and non-cancer samples were downloaded from the Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO). Gene ontol. enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway anal. of DEGs were analyzed using the Database for Annotation, Visualization, and Integrated Discovery. The R software package (SubpathwayMiner) was used to perform pathway anal. on DEGs affected by drugs found in the Connectivity Map (CMap) database. Protein-protein interaction (PPI) networks of DEGs were constructed using the Search Tool for the Retrieval of Interacting Genes online database and Cytoscape software. In order to identify potential novel drugs for DLBCL, the DLBCL-related pathways and drug-affected pathways were integrated. The results showed that 1927 DEGs were identified from TCGA and GEO. We found 54 significant pathways of DLBCL using KEGG pathway anal. By integrating pathways, we identified five overlapping pathways and 47 drugs that affected these pathways. The PPI network anal. results showed that the CDK2 is closely associated with three overlapping pathways (cell cycle, p53 signaling pathway, and small cell lung cancer). The further literature verification results showed that etoposide, rinotecan, methotrexate, resveratrol, and irinotecan have been used as classic clin. drugs for DLBCL. Anisomycin, naproxen, gossypol, vorinostat, emetine, mycophenolic acid and daunorubicin also act on DLBCL. It was found through bioinformatics anal. that paclitaxel in the drug-pathway network can be used as a potential novel drug for DLBCL. This study involved multiple reactions and reactants, such as 4-Benzyloxyphenol (cas: 103-16-2Electric Literature of C13H12O2).

4-Benzyloxyphenol (cas: 103-16-2) belongs to ethers. Volatile esters with characteristic odours are used in synthetic flavours, perfumes, and cosmetics. Certain volatile esters are used as solvents for lacquers, paints, and varnishes. Cyclic esters are called lactones, regardless of whether they are derived from an organic or inorganic acid. One example of an organic lactone is γ-valerolactone.Electric Literature of C13H12O2

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem

Immunoprognostic model of lung adenocarcinoma and screening of sensitive drugs was written by Liang, Pengchen;Li, Jin;Chen, Jianguo;Lu, Junyan;Hao, Zezhou;Shi, Junfeng;Chang, Qing;Zeng, Zeng. And the article was included in Scientific Reports in 2022.Safety of 4-Benzyloxyphenol The following contents are mentioned in the article:

Screening of mRNAs and lncRNAs associated with prognosis and immunity of lung adenocarcinoma (LUAD) and used to construct a prognostic risk scoring model (PRS-model) for LUAD. To analyze the differences in tumor immune microenvironment between distinct risk groups of LUAD based on the model classification. The CMap database was also used to screen potential therapeutic compounds for LUAD based on the differential genes between distinct risk groups. he data from the Cancer Genome Atlas (TCGA) database. We divided the transcriptome data into a mRNA subset and a lncRNA subset, and use multiple methods to extract mRNAs and lncRNAs associated with immunity and prognosis. We further integrated the mRNA and lncRNA subsets and the corresponding clin. information, randomly divided them into training and test set according to the ratio of 5:5. Then, we performed the Cox risk proportional anal. and cross-validation on the training set to construct a LUAD risk scoring model. Based on the risk scoring model, patients were divided into distinct risk group. Moreover, we evaluate the prognostic performance of the model from the aspects of Area Under Curve (AUC) anal., survival difference anal., and independent prognostic anal. We analyzed the differences in the expression of immune cells between the distinct risk groups, and also discuss the connection between immune cells and patient survival. Finally, we screened the potential therapeutic compounds of LUAD in the Connectivity Map (CMap) database based on differential gene expression profiles, and verified the compound activity by cytostatic assays. We extracted 26 mRNAs and 74 lncRNAs related to prognosis and immunity by using different screening methods. Two mRNAs (i.e., KLRC3 and RAET1E) and two lncRNAs (i.e., AL590226.1 and LINC00941) and their risk coefficients were finally used to construct the PRS-model. The risk score positions of the training and test set were 1.01056590 and 1.00925190, resp. The expression of mRNAs involved in model construction differed significantly between the distinct risk population. The one-year ROC areas on the training and test sets were 0.735 and 0.681. There was a significant difference in the survival rate of the two groups of patients. The PRS-model had independent predictive capabilities in both training and test sets. Among them, in the group with low expression of M1 macrophages and resting NK cells, LUAD patients survived longer. In contrast, the monocyte expression up-regulated group survived longer. In the CMap drug screening, three LUAD therapeutic compounds, such as resveratrol, methotrexate, and phenoxybenzamine, scored the highest. In addition, these compounds had significant inhibitory effects on the LUAD A549 cell lines. The LUAD risk score model constructed using the expression of KLRC3, RAET1E, AL590226.1, LINC00941 and their risk coefficients had a good independent prognostic power. The optimal LUAD therapeutic compounds screened in the CMap database: resveratrol, methotrexate and phenoxybenzamine, all showed significant inhibitory effects on LUAD A549 cell lines. This study involved multiple reactions and reactants, such as 4-Benzyloxyphenol (cas: 103-16-2Safety of 4-Benzyloxyphenol).

4-Benzyloxyphenol (cas: 103-16-2) belongs to ethers. Volatile esters with characteristic odours are used in synthetic flavours, perfumes, and cosmetics. Certain volatile esters are used as solvents for lacquers, paints, and varnishes. Esters contain a carbonyl center, which gives rise to 120° C–C–O and O–C–O angles. Unlike amides, esters are structurally flexible functional groups because rotation about the C–O–C bonds has a low barrier. Their flexibility and low polarity is manifested in their physical properties; they tend to be less rigid (lower melting point) and more volatile (lower boiling point) than the corresponding amides. Safety of 4-Benzyloxyphenol

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem

Immunoprognostic model of lung adenocarcinoma and screening of sensitive drugs was written by Liang, Pengchen;Li, Jin;Chen, Jianguo;Lu, Junyan;Hao, Zezhou;Shi, Junfeng;Chang, Qing;Zeng, Zeng. And the article was included in Scientific Reports in 2022.Computed Properties of C13H12O2 The following contents are mentioned in the article:

Screening of mRNAs and lncRNAs associated with prognosis and immunity of lung adenocarcinoma (LUAD) and used to construct a prognostic risk scoring model (PRS-model) for LUAD. To analyze the differences in tumor immune microenvironment between distinct risk groups of LUAD based on the model classification. The CMap database was also used to screen potential therapeutic compounds for LUAD based on the differential genes between distinct risk groups. he data from the Cancer Genome Atlas (TCGA) database. We divided the transcriptome data into a mRNA subset and a lncRNA subset, and use multiple methods to extract mRNAs and lncRNAs associated with immunity and prognosis. We further integrated the mRNA and lncRNA subsets and the corresponding clin. information, randomly divided them into training and test set according to the ratio of 5:5. Then, we performed the Cox risk proportional anal. and cross-validation on the training set to construct a LUAD risk scoring model. Based on the risk scoring model, patients were divided into distinct risk group. Moreover, we evaluate the prognostic performance of the model from the aspects of Area Under Curve (AUC) anal., survival difference anal., and independent prognostic anal. We analyzed the differences in the expression of immune cells between the distinct risk groups, and also discuss the connection between immune cells and patient survival. Finally, we screened the potential therapeutic compounds of LUAD in the Connectivity Map (CMap) database based on differential gene expression profiles, and verified the compound activity by cytostatic assays. We extracted 26 mRNAs and 74 lncRNAs related to prognosis and immunity by using different screening methods. Two mRNAs (i.e., KLRC3 and RAET1E) and two lncRNAs (i.e., AL590226.1 and LINC00941) and their risk coefficients were finally used to construct the PRS-model. The risk score positions of the training and test set were 1.01056590 and 1.00925190, resp. The expression of mRNAs involved in model construction differed significantly between the distinct risk population. The one-year ROC areas on the training and test sets were 0.735 and 0.681. There was a significant difference in the survival rate of the two groups of patients. The PRS-model had independent predictive capabilities in both training and test sets. Among them, in the group with low expression of M1 macrophages and resting NK cells, LUAD patients survived longer. In contrast, the monocyte expression up-regulated group survived longer. In the CMap drug screening, three LUAD therapeutic compounds, such as resveratrol, methotrexate, and phenoxybenzamine, scored the highest. In addition, these compounds had significant inhibitory effects on the LUAD A549 cell lines. The LUAD risk score model constructed using the expression of KLRC3, RAET1E, AL590226.1, LINC00941 and their risk coefficients had a good independent prognostic power. The optimal LUAD therapeutic compounds screened in the CMap database: resveratrol, methotrexate and phenoxybenzamine, all showed significant inhibitory effects on LUAD A549 cell lines. This study involved multiple reactions and reactants, such as 4-Benzyloxyphenol (cas: 103-16-2Computed Properties of C13H12O2).

4-Benzyloxyphenol (cas: 103-16-2) belongs to ethers. Esters are widespread in nature and are widely used in industry. In nature, fats are in general triesters derived from glycerol and fatty acids. Esters are responsible for the aroma of many fruits. Acyl chlorides and acid anhydrides alcoholysis is another way to produce esters. Acyl chlorides and acid anhydrides react with alcohols to produce esters. Anydrous conditions are recommended since both acyl chlorides and acid anhydrides react with water.Computed Properties of C13H12O2

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem

Design, synthesis, biological evaluation and molecular modeling of novel 1H-pyrazolo[3,4-d]pyrimidine derivatives as BRAF^V600E and VEGFR-2 dual inhibitors was written by Wang, Yuanyuan;Wan, Shanhe;Li, Zhonghuang;Fu, Yu;Wang, Guangfa;Zhang, Jiajie;Wu, Xiaoyun. And the article was included in European Journal of Medicinal Chemistry in 2018.Application of 103-16-2 The following contents are mentioned in the article:

Aiming to explore novel BRAF^V600E and VEGFR-2 dual inhibitors, a series of 1H-pyrazolo[3,4-d]pyrimidine derivatives were designed, synthesized and biol. evaluated. Most of the synthesized 1H-pyrazolo[3,4-d]pyrimidine compounds displayed moderate to high potent activity in both enzymic and cellular proliferation assays. Among these compounds, N-(4-chlorophenyl)-1-methyl-5-((1-methyl-1H-pyrazolo [3,4-d]pyrimidin-4-yl)oxy)-1H-benzo[d]imidazol-2-amine, 1-methyl-5-((1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl) oxy)-N-(p-tolyl)-1H-benzo[d]imidazol-2-amine, N-(4-bromophenyl)-1-methyl-5-((1-methyl-1H-pyrazolo [3,4-d]pyrimidin-4-yl)oxy)-1H-benzo[d]imidazol-2-amine and 1-methyl-5-((1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl) oxy)-N-(4-(trifluoromethoxy)phenyl)-1H-benzo[d]imidazol-2-amine showed remarkably high inhibitory activities against both BRAF^V600E and VEGFR-2 kinase comparable to pos. control Sorafenib. Particularly, compound 1-methyl-5-((1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl) oxy)-N-(4-(trifluoromethoxy)phenyl)-1H-benzo[d]imidazol-2-amine also showed potent anti-proliferative activity against BRAF^V600E-expressing A375 (IC₅₀ = 1.74 μM) and H-29 (IC₅₀ = 6.92 μM) as well as VEGFR-2-expressing HUVEC (IC₅₀ = 5.89 μM), which was also comparable to Sorafenib. Furthermore, kinase selectivity profile showed that 1-methyl-5-((1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl) oxy)-N-(4-(trifluoromethoxy)phenyl)-1H-benzo[d]imidazol-2-amine had almost poor or no significant inhibitory activity against wild-type BRAF and 15 other tested protein kinases. Flow cytometric anal. showed that compound 1-methyl-5-((1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl) oxy)-N-(4-(trifluoromethoxy)phenyl)-1H-benzo[d]imidazol-2-amine mainly arrested the A375 and HUVEC cell lines in the G₀/G₁ stage with a concentration-dependent effect. In addition, the mol. docking and mol. dynamics simulations suggested that 1-methyl-5-((1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl) oxy)-N-(4-(trifluoromethoxy)phenyl)-1H-benzo[d]imidazol-2-amine adopted a similar binding pattern with Sorafenib at the ATP-binding sites of BRAF^V600E and VEGFR-2. Taken together, these results indicated that compound 1-methyl-5-((1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl) oxy)-N-(4-(trifluoromethoxy)phenyl)-1H-benzo[d]imidazol-2-amine may serve as novel lead compound in research on more effective BRAF^V600E and VEGFR-2 dual inhibitors. This study involved multiple reactions and reactants, such as 4-Benzyloxyphenol (cas: 103-16-2Application of 103-16-2).

4-Benzyloxyphenol (cas: 103-16-2) belongs to ethers. Esters are widespread in nature and are widely used in industry. In nature, fats are in general triesters derived from glycerol and fatty acids. Esters are responsible for the aroma of many fruits. Esterification is the general name for a chemical reaction in which two reactants (typically an alcohol and an acid) form an ester as the reaction product. Esters are common in organic chemistry and biological materials.Application of 103-16-2

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem